The 10-second takeaway
For the quarter ended Dec. 31 (Q2), Cardiovascular Systems beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share grew.
Margins shrank across the board.
Cardiovascular Systems booked revenue of $25.3 million. The six analysts polled by S&P Capital IQ expected to see sales of $23.7 million on the same basis. GAAP reported sales were 28% higher than the prior-year quarter's $19.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.28. The five earnings estimates compiled by S&P Capital IQ averaged -$0.30 per share. GAAP EPS were -$0.28 for Q2 against -$0.23 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 76.5%, 40 basis points worse than the prior-year quarter. Operating margin was -20.2%, 160 basis points worse than the prior-year quarter. Net margin was -22.8%, 180 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $24.4 million. On the bottom line, the average EPS estimate is -$0.32.
Next year's average estimate for revenue is $96.8 million. The average EPS estimate is -$1.15.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cardiovascular Systems is buy, with an average price target of $15.30.
Is Cardiovascular Systems the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Cardiovascular Systems to My Watchlist.